Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Merck (NYSE:MRK) announced Tuesday that the European Commission approved its anti-cancer agent Welireg (belzutifan) as a ...

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer ...

Deputy Steve Lyles has had a rare form of kidney cancer for the past five years. To help Lyles in his fight, the Waukesha ...

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

The National Cancer Audit Collaborating Centre said prostate, kidney and colon cancers were the worst affected with ...

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

Patients with advanced kidney cancer who received an experimental vaccine after their tumors were removed were still ...

Avelumab maintenance with axitinib interruption was feasible in metastatic renal cell carcinoma responders, according to ...

There could be new hope on for kidney cancer patients. Researchers announced early results of an anti-tumor vaccine for patients with stage 3 or 4 kidney cancer, who face high recurrence risk.

Senior doctors responsible for monitoring cancer care in England and Wales are concerned failings in NHS services are contributing to up to half of patients are not getting the right treatment for ...